These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 7482872)

  • 1. Induction immunosuppression with antithymocyte globulin in renal transplantation using a variable dose according to the absolute number of CD3+ T cells.
    Abouna GM; Kumar MS; al-Abdullah IH; Loose J; Sullivan DK; Phillips K; Yost S; Seirka D
    Transplant Proc; 1995 Oct; 27(5):2676-8. PubMed ID: 7482872
    [No Abstract]   [Full Text] [Related]  

  • 2. Sequential monitoring of immunoregulatory T cell subsets in renal transplantation.
    Mestre M; González C; Griño JM; Valls A; Bonete J; Mané E; Corominas M; Bas J; Romeu A; Buendia E
    Transplant Proc; 1992 Feb; 24(1):73-5. PubMed ID: 1539351
    [No Abstract]   [Full Text] [Related]  

  • 3. Flow cytometric measurements in 104 anti-T-lymphocyte globulin treatments.
    Ekberg H; Persson NH; Olsson M; Lundell A; Bredberg A
    Transplant Proc; 1992 Dec; 24(6):2551-2. PubMed ID: 1465863
    [No Abstract]   [Full Text] [Related]  

  • 4. Induction therapy with antithymocyte globulin reduces the incidence of allograft rejection and improves graft survival in cadaver renal transplantation.
    Abouna GM; Kumar MS; Stephan R; Prior JE; Lyons P; Bulova SI; al-Abdullah IH
    Transplant Proc; 1993 Jun; 25(3):2241-2. PubMed ID: 8516886
    [No Abstract]   [Full Text] [Related]  

  • 5. OKT3 prophylaxis in kidney transplant recipients: drug monitoring by flow cytometry.
    Cinti P; Cocciolo P; Evangelista B; Orlandini AM; Bruzzone P; Renna Molajoni E; Cortesini R
    Transplant Proc; 1996 Dec; 28(6):3214-6. PubMed ID: 8962245
    [No Abstract]   [Full Text] [Related]  

  • 6. Comparison between three different antilymphocyte induction protocols in renal transplant recipients with delayed graft function.
    Sumrani N; Hong JH; DiBenedetto A; Clayton R; Miles AM; Markell MS; Distant DA; Fleishhacker J; Sommer BG
    Transplant Proc; 1996 Feb; 28(1):400-1. PubMed ID: 8644289
    [No Abstract]   [Full Text] [Related]  

  • 7. Effect of HLA matching and T- and B-cell crossmatch on acute rejection and graft survival following liver transplantation.
    Chen M; Wade J; Levy GA; Greig PD
    Transplant Proc; 1994 Oct; 26(5):2695-6. PubMed ID: 7940844
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical immunosuppression, lymphocyte subsets, and host defense mechanisms.
    Guttmann RD
    Transplant Proc; 1994 Aug; 26(4):1847. PubMed ID: 8066601
    [No Abstract]   [Full Text] [Related]  

  • 9. Optimization of cyclosporine monotherapy--long-term graft function.
    Birkeland SA; Elbirk A; Rohr N; Jørgensen KA
    Transplant Proc; 1994 Oct; 26(5):2501-6. PubMed ID: 7940767
    [No Abstract]   [Full Text] [Related]  

  • 10. Comparison of OKT3 and antithymocyte globulin as induction immunosuppressive agents in renal transplantation.
    Kitabayashi K; Munn SR; Sterioff S
    Transplant Proc; 1996 Jun; 28(3):1973-5. PubMed ID: 8658964
    [No Abstract]   [Full Text] [Related]  

  • 11. Randomized clinical trial of antithymocyte globulin induction in renal transplantation comparing a fixed daily dose with dose adjustment according to T cell monitoring.
    Abouna GM; al-Abdullah IH; Kelly-Sullivan D; Kumar MS; Loose J; Phillips K; Yost S; Seirka D
    Transplantation; 1995 Jun; 59(11):1564-8. PubMed ID: 7778170
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Depleting effect of antithymocyte globulin on T-lymphocyte subsets in kidney transplantation.
    Mestre M; Bas J; Alsina J; Grinyó JM; Buendia E
    Transplant Proc; 1999 Sep; 31(6):2254-5. PubMed ID: 10500565
    [No Abstract]   [Full Text] [Related]  

  • 13. Consequences of anti-OKT3 antibody development: OKT3 reuse and long-term graft survival.
    Shield CF
    Transplant Proc; 1993 Apr; 25(2 Suppl 1):81-2. PubMed ID: 8465434
    [No Abstract]   [Full Text] [Related]  

  • 14. Outcome of cadaveric renal transplantation by induction treatment in the cyclosporine era.
    Hariharan S; Alexander JW; Schroeder TJ; First MR
    Clin Transplant; 1996 Apr; 10(2):186-90. PubMed ID: 8664516
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized prospective study comparing OKT3 and antithymocyte globulins for treatment of the first acute cellular rejection of kidney allografts.
    Alamartine E; Bellakoul R; Berthoux F
    Transplant Proc; 1994 Feb; 26(1):273-4. PubMed ID: 8108975
    [No Abstract]   [Full Text] [Related]  

  • 16. OKT3 induction in 100 consecutive pancreas transplants.
    Stratta RJ; Taylor RJ; Lowell JA; Bynon JS; Cattral MS; Frisbie K; Miller S; Brennan DC
    Transplant Proc; 1994 Apr; 26(2):546-7. PubMed ID: 8171546
    [No Abstract]   [Full Text] [Related]  

  • 17. Does acute tubular necrosis affect renal transplant outcome? The impact of rejection episodes.
    Troppmann C; Almond PS; Payne WD; Dunn DL; Gores PF; Gruessner RW; Sutherland DE; Matas AJ; Najarian JS
    Transplant Proc; 1993 Feb; 25(1 Pt 2):905. PubMed ID: 8442263
    [No Abstract]   [Full Text] [Related]  

  • 18. Monitoring antithymocyte globulin in renal transplantation.
    Clark K
    Ann R Coll Surg Engl; 1996 Nov; 78(6):536-40. PubMed ID: 8943640
    [No Abstract]   [Full Text] [Related]  

  • 19. Five-year experience with a triple drug protocol in renal transplantation.
    Pallardó LM; Sánchez J; García J; Puig N; Sánchez P; Górriz JL; Cruz JM
    Transplant Proc; 1992 Feb; 24(1):56-7. PubMed ID: 1539342
    [No Abstract]   [Full Text] [Related]  

  • 20. Antilymphocyte induction immunosuppression in the post-Minnesota anti-lymphocyte globulin era: incidence of renal dysfunction and delayed graft function. A single center experience.
    Malinow L; Walker J; Klassen D; Oldach D; Schweitzer E; Bartlett ST; Weir MR
    Clin Transplant; 1996 Jun; 10(3):237-42. PubMed ID: 8826659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.